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COMMENTARY

COMMENTARY

Silencing synuclein at the synapse with PLK2

The signiﬁcance of α-synuclein (α-syn) phosphorylation to Parkinson disease (PD) pathology has been controversial since the
initial identiﬁcation of this posttranslational
modiﬁcation in intracellular Lewy bodies
(1, 2). The modiﬁcation of serine-129 (S129),
which appears to be the most common phosphorylation site on α-syn (3, 4), has had the
focus of attention. Although several different
kinase families have been linked to modiﬁcation of S129 in vitro, deﬁnitive in vivo evidence
that a given kinase family causes the modiﬁcation has been lacking (5). In addition to the
lack of clarity regarding which kinases phosphorylate α-syn in a physiologically relevant
context, it has been unclear whether phosphorylation of S129 is protective or harmful
to neurons. The most signiﬁcant problem in
this regard has been that genetic manipulation of α-syn at S129—by mutation to either
alanine or aspartate—has yielded varying results in cultured cells and different model

organisms, including ﬂies, worms, and rodents (5). Because the phosphorylation of
S129 appeared to have no consistent effect
on α-syn function in the cell, it has been
unclear whether the process does anything
more than reﬂect the magnitude of total
α-syn levels in diseased neurons. In their
article in PNAS, Oueslati et al. (6) now reveal a unique and unexpected effect coupled
to S129 phosphorylation.
In many studies of the phospho-speciﬁc
epitopes of different proteins, it has turned
out that knowing the identity of the kinase
that phosphorylates a given protein in a physiological context can be just as important as
knowing which speciﬁc residue is modiﬁed.
Oueslati et al. (6) show that the phosphorylation of S129 of α-syn is no exception. This
is because the kinase of interest, polo-like
kinase 2 (PLK2), not only phosphorylates
α-syn, but also escorts modiﬁed α-syn into
the autophagy pathway for degradation. This
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dual kinase/chaperone activity (Fig. 1) provides key insight into the signiﬁcance of
α-syn phosphorylation, because in the absence of chaperone activity of PLK2, it is
not clear that modiﬁcation of α-syn at S129
has any major functional impact.
The ﬁrst evidence that α-syn could be
phosphorylated at S129 by PLK family members came from a loss-of-function siRNA
screen by Elan Pharmaceuticals, which identiﬁed both PLK2 and PLK3 as potential
mediators of the modiﬁcation (7). Importantly, this study also demonstrated that
small-molecule inhibition and germ-line deletion of mouse Plk2 lead to decreased S129
phosphorylation in vivo. An ensuing study
by Lashuel and colleagues conﬁrmed the
ﬁnding, and further demonstrated the speciﬁcity of PLK2 and PLK3 for α-syn compared
with other synuclein isoforms (8). Two critical pieces of information in the PLK2/α-syn
connection were missing, however: namely,
an understanding of the functional consequences of the interaction and how it affects
α-syn pathology.
In addition to its kinase domain, PLK2
also contains a namesake polo-box domain,
which functions as a phospho-ser/thr binding
motif (9). Oueslati et al. (6) demonstrate that
after phosphorylating α-syn at S129, PLK2
binds α-syn via this polo-box domain and
escorts it into a degradation pathway, most
likely of autophagy/lysosomal origin (Fig. 1).
The precise identity of which autophagic
pathway is involved is unclear (macroautophagy vs. chaperone-mediated autophagy),
but PLK2-mediated α-syn degradation is
blocked by both early and late inhibitors of
autophagy and does not appear to involve
proteosomal activity.
Most importantly, this study by Oueslati
et al. (6) also shows that both PLK2 kinase
activity and an intact S129 site are required
for degradation of excess α-syn in the rat
brain. Thus, less α-syn protein accumulated
and fewer neurons died when rat brain
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Fig. 1. Dual function of PLK2 in the phosphorylation and degradation of neuronal α-syn. Coordinate expression of
α-syn and PLK2 in the same neuronal compartment promotes speciﬁc phosphorylation of α-syn at S129 by the PLK2
kinase domain. Upon phosphorylation (p-S129), α-syn is bound by the PLK2 polo-box domain. Formation of this binary
complex promotes trafﬁcking of α-syn into the autophagy/lysosomal pathway, which ultimately leads to its degradation. Inhibition of lysosomal function may, however, promote the accumulation of phosphorylated α-syn. Neurons
may deal with excess α-syn by storing it in the form of large intracellular aggregates (Lewy bodies) or by releasing into
the extracellular space, thus leading to cell-to-cell transmission.
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neurons were cotransduced in vivo with
viral vectors for both human α-syn and
PLK2 than when the brains were injected
with α-syn vectors alone. A vector encoding
kinase-dead PLK2, however, was ineffective
at reducing α-syn levels. Furthermore, when
the neurons were transduced with a viral
vector encoding S129A–α-syn (which cannot undergo phosphorylation), cotransduction of PLK2 did not affect α-syn protein
levels and neuronal loss. Previous studies
have shown that when other putative S129
kinases from the G protein-coupled receptor
kinase family are coexpressed with α-syn, the
α-syn protein levels and neuronal survival are
not changed, despite the levels of phosphorylated S129–α-syn going up (10).
It is notable that PLK2, unlike other PLK
family members, appears to be enriched in
postsynaptic dendrites in the brain, and is
transcriptionally up-regulated in response to
synaptic hyperactivity (11, 12). Within this
context, PLK2 activity is required for homeostatic synaptic scaling in hyperstimulated neurons and results in decreased dendritic spine
density and AMPA receptor down-regulation
(13, 14). Although this may at ﬁrst appear
irrelevant to α-syn, which is mostly located
at presynaptic terminals in neurons, it
should be noted that increased synaptic activity promotes α-syn secretion from neurons, and that phosphorylated α-syn is
enriched in the secreted fraction of some cell
types (15, 16). Given the suggestion that
α-syn secretion is a key step in a prion-like
cell-to-cell transfer of α-syn pathology and
thereby contributes to progression of PD
symptoms (17), the ﬁndings by Oueslati
et al. (6) suggest that PLK2 might inﬂuence
transmission of misfolded α-syn variants.
Interestingly, the autophagy/lysosomal
pathway by which PLK2 facilitates α-syn degradation has already been implicated in the
pathogenesis of PD (18, 19). Regardless of
which distinct autophagic mechanism is used
for α-syn clearance, disruption of lysosomal
function—either by genetic changes or toxic
insults—would be expected to result in accumulation of excess phosphorylated α-syn
(Fig. 1). Because phosphorylated α-syn is
enriched in Lewy bodies in PD patients, it
is possible that these inclusions form in response to lysosomal failure in the context
of high synaptic activity. Under these circumstances, α-syn would be expected to undergo
higher rates of cell-to-cell transfer and become phosphorylated by the increased levels
of PLK2 in postsynaptic neurons. In the absence of proper lysosomal function, however,
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α-syn/PLK2 complexes would fail to become
degraded, and could conceivably trigger α-syn
aggregation or further release into the extracellular space (Fig. 1) (16). Application of the
recently described α-syn transmission model
of PD to Plk2−/− mice, which are viable into
adulthood, would provide insight into whether
this hypothesis is valid (20).
Despite the ﬁndings of Oueslati et al. (6)
providing new exciting directions for future
PD research, the immediate therapeutic
implications of the results are less clear. The

authors’ results suggest clearly that increased PLK2 activity would be beneﬁcial,
although this effect would be challenging
to achieve with small molecules. Preventing α-syn dephosphorylation by targeting
the pS129 phosphatase is similarly unlikely to provide beneﬁt, because phosphorylation of α-syn is not sufﬁcient for
protection in the absence of increased
PLK2 chaperone activity (Fig. 1). In this
context it would appear that gene therapy

aimed at PLK2 gene overexpression or
modulation of its breakdown using miRNA
technology—with all of the challenges this
would entail—are currently the most likely
means by which one could increase PLK2
levels in the brain.
However, one then has to ask the question
whether chronically increased PLK2 activity
in neurons is likely to be a good thing. Viral
vector-mediated overexpression of PLK2 in
the rat model used by Oueslati et al. (6) did
not cause toxicity in the timeframe of their
study, but this does not exclude detrimental
effects in a chronic setting. Brains from patients with Alzheimer’s disease and Lewy
body disease have been shown to contain increased levels of PLK2 (8). This ﬁnding is
possibly because of the well-described loss
of calcium homeostasis in diseased neurons,
which mimics synaptic hyperactivity and
would promote PLK2 up-regulation (13). Increased calcium levels in diseased neurons
are also linked to synaptic dysfunction and
reduced spine density—two effects associated with PLK2 activation (21). Therefore,
excessive PLK2 activity for prolonged periods might be harmful to neurons, despite
it promoting α-syn degradation. Future
studies will hopefully address this paradox
and provide a clear answer to whether
PLK2 is a friend or foe in the battle against
neurodegenerative disease.
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